title: [Fusariosis diagnosed in the laboratory of an UH in Tunisia: epidemiological, clinical and mycological study].
abstract: The genus Fusarium, initially known for its important agro-economic impact, is more and more often implicated in human pathology. In fact, multiples allergic, toxic and infectious manifestations are more reported in immunocompetent and immunocompromised hosts. The objective of our study was to analyse the epidemiological, mycological and clinical features of fusariosis reported in our CHU. Eighty-seven cases of Fusarium infections were collected: 34 cases of onychomycosis (39%), 26 cases of intertrigos (30%), 25 cases of keratomycosis (29%), one case of atypical invasive fusariosis due to Fusarium oxysporum species complex (FOSC) and one case of localized gingivolabial fusariosis due to Fusarium solani species complex (FSSC) in a patient with leukemia in phase of deep bone marrow aplasia, whose outcome was favorable after exiting of aplasia period and a treatment by amphotericine B. The case of pseudotumoral cutaneous fusariosis to F. oxysporum complicated with osteolysis and septic arthritis occurred in a pregnant woman without any immune deficit. The evolution was fatal in spite of prescription of multiple systemic antifungals. Concerning keratomycosis, Fusarium was the first agent responsible for these infections (43%). The corneal traumatism was found in 37.5% of cases and FSSC was the most isolated (72%). For superficial dermatomycosis, Fusarium was the third agent of onychomycosis in molds (25%). The most isolated species were FSSC (68%) and FOSC (20%). The intertrigo frequency was 0.07% and they were mostly caused by FSSC (84%) and FOSC (16%). Fusarium is an important cause of mold infections in our region. So, the species identification is useful because some species are resistant to the most common systemic antifungal agents.
authors.affiliation: Laboratoire de biologie moléculaire parasitaire et fongique, faculté de médecine, rue Magida Boulila, 3029 Sfax, Tunisie.
authors.forename: S
authors.initials: S
authors.lastname: Néji
authors.forename: H
authors.initials: H
authors.lastname: Trabelsi
authors.forename: F
authors.initials: F
authors.lastname: Cheikhrouhou
authors.forename: H
authors.initials: H
authors.lastname: Sellami
authors.forename: R
authors.initials: R
authors.lastname: Guidara
authors.forename: A
authors.initials: A
authors.lastname: Trigui
authors.forename: J
authors.initials: J
authors.lastname: Feki
authors.forename: S
authors.initials: S
authors.lastname: Boudaya
authors.forename: H
authors.initials: H
authors.lastname: Turki
authors.forename: F
authors.initials: F
authors.lastname: Makni
authors.forename: A
authors.initials: A
authors.lastname: Ayadi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use; D019411:Clinical Laboratory Techniques / Q000706:statistics & numerical data; D003320:Corneal Ulcer / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D015821:Eye Infections, Fungal / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D060585:Fusariosis / Q000175:diagnosis / Q000453:epidemiology* / Q000382:microbiology* / Q000628:therapy; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D008875:Middle Aged; D014009:Onychomycosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D012189:Retrospective Studies; D014416:Tunisia / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000935:Antifungal Agents